{"id":9824,"date":"2021-05-17T10:03:36","date_gmt":"2021-05-17T17:03:36","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=9824"},"modified":"2021-05-18T10:23:01","modified_gmt":"2021-05-18T17:23:01","slug":"covid-19-literature-situation-report-may-17-2021","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/05\/17\/covid-19-literature-situation-report-may-17-2021\/","title":{"rendered":"COVID-19 Literature Situation Report May 17, 2021"},"content":{"rendered":"<p>The scientific literature on COVID-19 is rapidly evolving and these articles were selected for review based on their relevance to Washington State decision making around COVID-19 response efforts. Included in these Lit Reps are some manuscripts that have been made available online as pre-prints but have not yet undergone peer review. Please be aware of this when reviewing articles included in the Lit Reps.<\/p>\n<p><em>Today&#8217;s summary is based on a review of 888 articles (826 published, 62 in preprint)<\/em><\/p>\n<p><strong><a href=\"https:\/\/depts.washington.edu\/pandemicalliance\/wordpress\/wp-content\/uploads\/2021\/05\/LitRep_20210517.docx.pdf\">View the PDF version here.<\/a><\/strong><\/p>\n<h2>Key Takeaways<\/h2>\n<ul>\n<li style=\"font-weight: 400\"><b>Interim results from a large study of US healthcare personnel indicated that one dose of either the Pfizer-BioNTech or Moderna vaccines was 82% effective against symptomatic COVID-19 and 2 doses were 94% effective.<\/b> <a href=\"https:\/\/doi.org\/10.15585\/mmwr.mm7020e2\"><span style=\"font-weight: 400\">More<\/span><\/a><\/li>\n<li style=\"font-weight: 400\"><b>On May 12<\/b><b>th<\/b><b>, 2021, the Advisory Committee on Immunization Practices made an interim recommendation for the use of the Pfizer-BioNTech vaccine among adolescents aged 12-15, following the FDA expansion of the Emergency Use Authorization eligibility to include this age group.<\/b> <a href=\"https:\/\/doi.org\/10.15585\/mmwr.mm7020e1\"><span style=\"font-weight: 400\">More<\/span><\/a><\/li>\n<li style=\"font-weight: 400\"><b>Analysis of sera from participants in the Moderna vaccine trial (n=24) found that most maintained both binding and functional antibodies against the B.1.1.7, B.1.351, P.1, B.1.429, and B.1.526 SARs-CoV-2 variants for 6 months, although at lower levels relative to wildtype and D614G. <\/b><a href=\"https:\/\/doi.org\/10.1101\/2021.05.13.444010\"><span style=\"font-weight: 400\">More<\/span><\/a><\/li>\n<li style=\"font-weight: 400\"><b>The SARS-CoV-2 <\/b><b>B.1.617 and B.1.618 strains currently circulating in India were somewhat resistant to neutralization by sera from convalescent individuals, vaccine-elicited antibodies<\/b><b>,<\/b><b> and therapeutic monoclonal antibodies; but not enough to suggest that current vaccines will not be protective.<\/b> <a href=\"https:\/\/doi.org\/10.1101\/2021.05.14.444076\"><span style=\"font-weight: 400\">More<\/span><\/a><\/li>\n<\/ul>\n<div id=\"uw-accordion-shortcode\">\n<h3>Article Summaries<\/h3>\n<div class=\"js-accordion\" data-accordion-prefix-classes=\"uw-accordion-shortcode\">\n<div class=\"js-accordion__panel\" >\n<h2 class=\"js-accordion__header\"><span style=\"font-weight: 400\">Transmission<\/span><\/h2>\n<div class=\"su-posts su-posts-default-loop\">\n<div id=\"su-post-9826\" class=\"su-post\">\n<h5 class=\"su-post-title\">Asymptomatic SARS-CoV-2-Infected Children Attending Hospital with Non-COVID-19 Diagnoses, March 2020-February 2021<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">A surveillance study conducted between March 1, 2020 and February 21, 2021 in the UK found that out of 1,427 pediatric patients admitted to the hospital, 80 (5.6%) tested positive for SARS-CoV-2, of which 52 (65%) had symptoms compatible with COVID-19, 16 (20%) were asymptomatic, and 12 (15%) were \u201cunclear\u201d because of overlapping symptoms between COVID-19 and a co-occurring illness. During months when schools were open (June, September-December), there was a 1.65-fold increase in the mean percentage of new asymptomatic SARS-CoV-2 infections among admitted children compared to when schools were closed (March-May, July-August, January-February).\u00a0<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Mann et al.\u00a0(May 2021). Asymptomatic SARS-CoV-2-Infected Children Attending Hospital with Non-COVID-19 Diagnoses, March 2020-February 2021. Journal of Infection. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1016\/j.jinf.2021.05.002\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1016\/j.jinf.2021.05.002<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"js-accordion__panel\" >\n<h2 class=\"js-accordion__header\">T<span style=\"font-weight: 400\">esting and Treatment<\/span><\/h2>\n<div class=\"su-posts su-posts-default-loop\">\n<div id=\"su-post-9830\" class=\"su-post\">\n<h5 class=\"su-post-title\">Seven-Day COVID-19 Quarantine May Be Too Short Assessing Post-Quarantine Transmission Risk in Four University Cohorts<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><i><span style=\"font-weight: 400\">[Pre-print, not peer-reviewed]<\/span><\/i><span style=\"font-weight: 400\"> A cohort study conducted at four US universities between September 2020 and February 2021 found that a seven-day quarantine period may not be sufficient to maintain a 5% transmission risk threshold, and that risk depends on the strictness of quarantine measures. The study compared \u201cstrict quarantine\u201d, which included designated housing with private rooms and meal delivery, versus \u201cnon-strict quarantine\u201d, which allowed individuals to interact with other household members. <\/span><span style=\"font-weight: 400\">Among 418 individuals who were quarantined and who eventually tested positive, 11%, 4.2%, and 1.2% were negative and asymptomatic on days 7, 10 and 14, respectively. 6% of individuals tested positive after day 7 in strict quarantine, versus 14% in non-strict quarantine, which may have been explained by exposure during the quarantine period.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Liu et al.\u00a0(May 15, 2021). Seven-Day COVID-19 Quarantine May Be Too Short Assessing Post-Quarantine Transmission Risk in Four University Cohorts. Pre-print downloaded May 17 from <\/span><\/i><a href=\"https:\/\/doi.org\/10.1101\/2021.05.12.21257117\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1101\/2021.05.12.21257117<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<div id=\"su-post-9828\" class=\"su-post\">\n<h5 class=\"su-post-title\">Convalescent Plasma in Patients Admitted to Hospital with COVID-19 (RECOVERY): A Randomised Controlled, Open-Label, Platform Trial<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Among patients hospitalized with COVID-19, convalescent plasma treatment did not improve 28-day mortality (RR = 1.0), time to hospital discharge (RR = 0.99), or result in a significant difference in the proportion of patients who either received invasive mechanical ventilation or died (RR = 0.99), according to results from the RECOVERY trial in the UK. 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days, and the mortality rate ratio was similar among all prespecified subgroups of patients, including those who did not have detectable SARS-CoV-2 antibodies at randomization. <\/span><i><span style=\"font-weight: 400\">[EDITORIAL NOTE: A pre-print related to this manuscript was summarized on March 11, 2021].<\/span><\/i><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Horby et al.\u00a0(May 14, 2021). Convalescent Plasma in Patients Admitted to Hospital with COVID-19 (RECOVERY): A Randomised Controlled, Open-Label, Platform Trial. The Lancet. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1016\/S0140-6736(21)00897-7\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1016\/S0140-6736(21)00897-7<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"js-accordion__panel\" >\n<h2 class=\"js-accordion__header\">Vaccines and Immunity<\/h2>\n<div class=\"su-posts su-posts-default-loop\">\n<div id=\"su-post-9848\" class=\"su-post\">\n<h5 class=\"su-post-title\">The Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12\u201315 Years \u2014 United States, May 2021<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">On May 12<\/span><span style=\"font-weight: 400\">th<\/span><span style=\"font-weight: 400\">, 2021, the Advisory Committee on Immunization Practices (ACIP) made an interim recommendation for the use of the Pfizer-BioNTech vaccine among adolescents aged 12-15, following the expansion of the FDA Emergency Use Authorization age eligibility to include this age group. The ACIP considered evidence from a systematic review of published and unpublished evidence of benefits and harms, the importance of COVID-19 as a public health concern, and issues regarding resource use and patients\u2019 and parents\u2019 values and preferences. <\/span><span style=\"font-weight: 400\">Evidence was primarily guided by a randomized, double-blind, placebo-controlled Phase II\/III clinical trial that found 100% efficacy in preventing symptomatic, laboratory-confirmed COVID-19 in adolescents aged 12\u201315 years without evidence of previous SARS-CoV-2 infection.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Wallace et al.\u00a0(May 14, 2021). The Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12\u201315 Years \u2014 United States, May 2021. MMWR. Morbidity and Mortality Weekly Report. <\/span><\/i><a href=\"https:\/\/doi.org\/10.15585\/mmwr.mm7020e1\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.15585\/mmwr.mm7020e1<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<div id=\"su-post-9846\" class=\"su-post\">\n<h5 class=\"su-post-title\">Seroconversion Rates Following COVID-19 Vaccination amongst Patients with Malignant Disease- the Impact of Diagnosis and Cancer-Directed Therapies<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><i><span style=\"font-weight: 400\">[Pre-print, not peer-reviewed]<\/span><\/i><span style=\"font-weight: 400\"> Among patients with cancer (n = 201) who were fully vaccinated with the Pfizer-BioNTech, Moderna, or Johnson &amp; Johnson\/Janssen vaccines, the majority (94%) showed seroconversion for anti-spike protein IgG. Lower seroconversion frequencies were observed for patients with <\/span><span style=\"font-weight: 400\">hematological malignancies (85%), particularly recipients of anti-CD20 therapies (70%) and stem cell transplantation (74%), compared to patients with solid organ tumors (98%). Patients receiving immune checkpoint inhibitor therapy (97%) or hormonal therapies (100%) also had high seroconversion. Overall, IgG titers were higher among those who received mRNA vaccines.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Thakkar et al.\u00a0(May 14, 2021). Seroconversion Rates Following COVID-19 Vaccination amongst Patients with Malignant Disease- the Impact of Diagnosis and Cancer-Directed Therapies. Pre-print downloaded May 17 from <\/span><\/i><a href=\"https:\/\/doi.org\/10.1101\/2021.05.07.21256824\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1101\/2021.05.07.21256824<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<div id=\"su-post-9844\" class=\"su-post\">\n<h5 class=\"su-post-title\">The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India Provide Partial Resistance to Vaccine-Elicited and Therapeutic Monoclonal Antibodies<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><i><span style=\"font-weight: 400\">[Pre-print, not peer-reviewed]<\/span><\/i><span style=\"font-weight: 400\"> The SARS-CoV-2 <\/span><span style=\"font-weight: 400\">B.1.617 and B.1.618 strains currently circulating in India were found to have specific spike protein mutations (B.1.617 = L452R\/E484Q\/D614G\/P681R, B.1.618 = \u0394145-146\/E484K\/D614G) that were somewhat resistant to neutralization by sera from convalescent individuals, vaccine-elicited antibodies, and therapeutic monoclonal antibodies; but not enough to suggest that current vaccines will not be protective. A study generating pseudoviruses found that those with B.1.617 and B.1.618 spike proteins had an average of 3.9-fold and 2.7-fold <\/span><span style=\"font-weight: 400\">reductions<\/span><span style=\"font-weight: 400\"> in the <\/span><span style=\"font-weight: 400\">half maximal <\/span><span style=\"font-weight: 400\">inhibitory concentration for convalescent sera and antibodies from the Pfizer-BioNTech and Moderna vaccines, respectively, which the authors suggest could be due to the L452R, E484Q, and E484K mutations. Both variants also had some resistance to <\/span><span style=\"font-weight: 400\">the monoclonal antibodies made by Regeneron<\/span><span style=\"font-weight: 400\">.\u00a0<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Tada et al.\u00a0(May 16, 2021). The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India Provide Partial Resistance to Vaccine-Elicited and Therapeutic Monoclonal Antibodies. Pre-print downloaded May 17 from <\/span><\/i><a href=\"https:\/\/doi.org\/10.1101\/2021.05.14.444076\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1101\/2021.05.14.444076<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<div id=\"su-post-9842\" class=\"su-post\">\n<h5 class=\"su-post-title\">Cellular Immunity Predominates over Humoral Immunity after the First Dose of COVID-19 Vaccines in Solid Organ Transplant Recipients<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><i><span style=\"font-weight: 400\">[Pre-print, not peer-reviewed]<\/span><\/i><span style=\"font-weight: 400\"> Among solid organ transplant recipients (n = 40) and age-matched controls (n = 70), <\/span><span style=\"font-weight: 400\">antibodies were detected in only <\/span><span style=\"font-weight: 400\">5% of<\/span><span style=\"font-weight: 400\"> transplant recipients versus 80% of controls, though specific CD4 and\/or CD8 T-cells were more frequently found in both transplant recipients <\/span><span style=\"font-weight: 400\">(24<\/span><span style=\"font-weight: 400\">%) and controls (84%)<\/span><span style=\"font-weight: 400\">.<\/span><span style=\"font-weight: 400\"> IgG and neutralization activity were also higher after vaccination with one of the mRNA vaccines compared to the Oxford-AstraZeneca vaccine, while CD4 and CD8 T-cell levels were higher after the Oxford-AstraZeneca vaccine. The authors <\/span><span style=\"font-weight: 400\">suggest <\/span><span style=\"font-weight: 400\">that antibody assessments alone are not sufficient to identify a vaccine response, and analyses of both humoral and cellular immunity will be important.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Schmidt et al.\u00a0(May 14, 2021). Cellular Immunity Predominates over Humoral Immunity after the First Dose of COVID-19 Vaccines in Solid Organ Transplant Recipients. Pre-print downloaded May 17 from <\/span><\/i><a href=\"https:\/\/doi.org\/10.1101\/2021.05.07.21256809\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1101\/2021.05.07.21256809<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<div id=\"su-post-9840\" class=\"su-post\">\n<h5 class=\"su-post-title\">Risk of SARS-CoV-2 Reinfection in a University Student Population<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">The risk of SARS-CoV-2 reinfection among college students with prior infection was 2.2% (n = 16,101, 2,021 with and 14,080 without previous infection), while estimated protection from previous infection was 84% among students tested in fall 2020 and spring 2021 semesters at a large university in South Carolina. All students with access to main campus facilities were required to receive PCR testing in the fall, and students living in university housing were retested weekly. The median time to reinfection was 129 days, or about 4 months.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Rennert and McMahan. (May 16, 2021). Risk of SARS-CoV-2 Reinfection in a University Student Population. Clinical Infectious Diseases. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1093\/cid\/ciab454\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1093\/cid\/ciab454<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<div id=\"su-post-9838\" class=\"su-post\">\n<h5 class=\"su-post-title\">Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel \u2014 33 U.S. Sites, January\u2013March 2021<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Among US healthcare personnel, one dose of either the Pfizer-BioNTech or Moderna vaccines was 82% effective against symptomatic COVID-19, and 2 doses were 94% effective. Interim results from a test-negative case-control study conducted in 25 states and e<\/span><span style=\"font-weight: 400\">nrolling 623 case-patients and 1,220 controls as of March 18, 2021<\/span><span style=\"font-weight: 400\"> indicate that vaccine effectiveness is similar to vaccine efficacy reported in clinical trials. <\/span><span style=\"font-weight: 400\">The effectiveness of a single dose was measured during the interval from 14 days after the first dose through 6 days after the second dose.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Pilishvili et al.\u00a0(May 14, 2021). Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel \u2014 33 U.S. Sites, January\u2013March 2021. MMWR. Morbidity and Mortality Weekly Report. <\/span><\/i><a href=\"https:\/\/doi.org\/10.15585\/mmwr.mm7020e2\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.15585\/mmwr.mm7020e2<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<div id=\"su-post-9836\" class=\"su-post\">\n<h5 class=\"su-post-title\">Durability of MRNA-1273-Induced Antibodies against SARS-CoV-2 Variants<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><i><span style=\"font-weight: 400\">[Pre-print, not peer-reviewed]<\/span><\/i><span style=\"font-weight: 400\"> An analysis of sera from participants in the Moderna vaccine trial (n=24) found that most individuals maintained both binding and functional antibodies against the B.1.1.7, B.1.351, P.1, B.1.429, and B.1.526 SARs-CoV-2 variants for 6 months, although at lower levels relative to wildtype and D614G. The B.1.1.7 lineage had little impact on antibody recognition and function, while B.1.351 had a greater effect, ranging from 3 to 15-fold reductions, and the other variants had intermediate impacts. The authors posit that the differential effects of the B.1.351 mutation on antibody response may be due to certain immune pressures that favor mutations like E484K.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Pegu et al.\u00a0(May 16, 2021). Durability of MRNA-1273-Induced Antibodies against SARS-CoV-2 Variants. Pre-print downloaded May 17 from <\/span><\/i><a href=\"https:\/\/doi.org\/10.1101\/2021.05.13.444010\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1101\/2021.05.13.444010<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<div id=\"su-post-9834\" class=\"su-post\">\n<h5 class=\"su-post-title\">Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca Vaccines on Covid-19 Related Symptoms, Hospital Admissions, and Mortality in Older Adults in England: Test Negative Case-Control Study<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">A case-control study of the effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines among adults aged 70 and older (n = 156,930) found that one dose of either vaccine was about 80% effective at preventing hospital admission with COVID-19, and a single dose of Pfizer-BioNTech was 85% effective at preventing death (follow-up was insufficient to assess the effect of Oxford-AstraZeneca on mortality), with protection maintained for at least 6 weeks.\u00a0<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Lopez Bernal et al.\u00a0(May 13, 2021). Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca Vaccines on Covid-19 Related Symptoms, Hospital Admissions, and Mortality in Older Adults in England: Test Negative Case-Control Study. BMJ.<\/span><\/i> <a href=\"https:\/\/doi.org\/10.1136\/bmj.n1088\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1136\/bmj.n1088<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<div id=\"su-post-9832\" class=\"su-post\">\n<h5 class=\"su-post-title\">Anti-SARS-CoV-2 Antibodies Persist for up to 13 Months and Reduce Risk of Reinfection<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><i><span style=\"font-weight: 400\">[Pre-print, not peer-reviewed]<\/span><\/i><span style=\"font-weight: 400\"> A longitudinal study of antibody responses among healthcare workers in France, 916 of whom had not had COVID-19 and 393 who were convalescent, found that almost all convalescent individuals (96%) had persistence of anti-S IgG antibodies one year after infection. From month 1 until months 7-9 after infection, <\/span><span style=\"font-weight: 400\">SARS-CoV-2 antibodies decreased, with men showing a slower decay of anti-N and a faster decay of anti-S antibodies than women. By months 11-13, anti-N decreased while anti-S stabilized. 69 individuals who were SARS-CoV-2 negative at baseline eventually tested positive, (incidence of 12.22 per 100 person-years) versus one with prior infection (0.40 per 100 person-years), for a relative reduction in the incidence of SARS-CoV-2 reinfection of 96.7%. After vaccination, anti-S antibodies significantly increased to levels found to neutralize the <\/span><span style=\"font-weight: 400\">D614G, B.1.1.7, and B.1.351 variants in the subset of isolates tested, with antibody level independent of <\/span><span style=\"font-weight: 400\">pre-vaccination IgG levels, type of vaccine, and number of doses.\u00a0<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Gallais et al.\u00a0(May 14, 2021). Anti-SARS-CoV-2 Antibodies Persist for up to 13 Months and Reduce Risk of Reinfection. Pre-print downloaded May 17 from <\/span><\/i><a href=\"https:\/\/doi.org\/10.1101\/2021.05.07.21256823\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1101\/2021.05.07.21256823<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"js-accordion__panel\" >\n<h2 class=\"js-accordion__header\"><span style=\"font-weight: 400\">Clinical Characteristics and Health Care Setting<\/span><\/h2>\n<div class=\"su-posts su-posts-default-loop\">\n<div id=\"su-post-9850\" class=\"su-post\">\n<h5 class=\"su-post-title\">A Retrospective Cohort Study of 12,306 Pediatric COVID-19 Patients in the United States<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">A retrospective cohort study found that a<\/span><span style=\"font-weight: 400\">mong 12,306 <\/span><span style=\"font-weight: 400\">pediatric patients with<\/span><span style=\"font-weight: 400\"> lab-confirmed<\/span><span style=\"font-weight: 400\"> COVID-19 in the US<\/span><span style=\"font-weight: 400\">, <\/span><span style=\"font-weight: 400\">5% were<\/span><span style=\"font-weight: 400\"> hospitaliz<\/span><span style=\"font-weight: 400\">ed, <\/span><span style=\"font-weight: 400\">1<\/span><span style=\"font-weight: 400\">8<\/span><span style=\"font-weight: 400\">% need<\/span><span style=\"font-weight: 400\">ed<\/span><span style=\"font-weight: 400\"> critical care services and 4% requir<\/span><span style=\"font-weight: 400\">ed<\/span><span style=\"font-weight: 400\"> mechanical ventilation. 1<\/span><span style=\"font-weight: 400\">4<\/span><span style=\"font-weight: 400\">% experienced gastrointestinal symptoms, 8% had dermatological symptoms (rash), <\/span><span style=\"font-weight: 400\">5<\/span><span style=\"font-weight: 400\">% had headache, and 1<\/span><span style=\"font-weight: 400\">9<\/span><span style=\"font-weight: 400\">% had other symptoms <\/span><span style=\"font-weight: 400\">(<\/span><span style=\"font-weight: 400\">fever, malaise, myalgia, arthralgia and altered smell or taste<\/span><span style=\"font-weight: 400\">)<\/span><span style=\"font-weight: 400\">. The risk of hospitalization was <\/span><span style=\"font-weight: 400\">higher <\/span><span style=\"font-weight: 400\">among non-Hispanic Black (RR = 2.0) and Hispanic children (RR = 1.3) compared with non-Hispanic white children.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Parcha et al.\u00a0(May 2021). A Retrospective Cohort Study of 12,306 Pediatric COVID-19 Patients in the United States. Scientific Reports. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1038\/s41598-021-89553-1\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1038\/s41598-021-89553-1<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"js-accordion__panel\" >\n<h2 class=\"js-accordion__header\"><span style=\"font-weight: 400\">Mental Health and Personal Impact<\/span><\/h2>\n<div class=\"su-posts su-posts-default-loop\">\n<div id=\"su-post-9852\" class=\"su-post\">\n<h5 class=\"su-post-title\">Psychological Distress, Persistent Physical Symptoms, and Perceived Recovery After COVID-19 Illness<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Patients experiencing COVID-19-related post-traumatic stress disorder (PTSD) and depression had a higher burden of persistent physical symptoms and were less likely to report feeling recovered 3 months after illness onset, according to a study of adults hospitalized between March 26 and May 27, 2020 in New York. <\/span><span style=\"font-weight: 400\">Thirty-six percent of patients reported full recovery from COVID-19 at follow-up, 24% had COVID-related PTSD, 18% had depression, and 12% met the criteria for both. The most common persistent physical symptoms were body aches (24%), fatigue (20%), shortness of breath (19%), and headache (13%). In adjusted models, the association between depression and physical symptoms became nonsignificant (OR = 3.1) while the association remained borderline significant for PTSD\u00a0and physical symptoms (OR = 4.9).<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Liyanage-Don et al.\u00a0(May 13, 2021). Psychological Distress, Persistent Physical Symptoms, and Perceived Recovery After COVID-19 Illness. Journal of General Internal Medicine. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1007\/s11606-021-06855-w\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1007\/s11606-021-06855-w<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"js-accordion__panel\" >\n<h2 class=\"js-accordion__header\"><span style=\"font-weight: 400\">Modeling and Prediction<\/span><\/h2>\n<div class=\"su-posts su-posts-default-loop\">\n<div id=\"su-post-9854\" class=\"su-post\">\n<h5 class=\"su-post-title\">Risk of COVID-19 Epidemic Resurgence with the Introduction of Vaccination Passes<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><i><span style=\"font-weight: 400\">[Pre-print, not peer-reviewed]<\/span><\/i><span style=\"font-weight: 400\"> A SIR model simulating the impact of vaccine passes or passports on SARS-CoV-2 dynamics found that different restrictions for passholders and unvaccinated individuals can result in a wide variety of epidemic trajectories, some of which may introduce new waves of infections. For example, while passholders may have fewer restrictions initially compared to the rest of the population, the authors assumed that immunity would wane over time, necessitating re-vaccination or further restrictions among vaccinated persons. The authors concluded that lowering restrictions for vaccine passholders would only be effective in the context of strict restrictions for other members of the population.\u00a0<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Krueger et al.\u00a0(May 14, 2021). Risk of COVID-19 Epidemic Resurgence with the Introduction of Vaccination Passes. Pre-print downloaded May 17 from <\/span><\/i><a href=\"https:\/\/doi.org\/10.1101\/2021.05.07.21256847\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1101\/2021.05.07.21256847<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"js-accordion__panel\" >\n<h2 class=\"js-accordion__header\"><span style=\"font-weight: 400\">Public Health Policy and Practice<\/span><\/h2>\n<div class=\"su-posts su-posts-default-loop\">\n<div id=\"su-post-9856\" class=\"su-post\">\n<h5 class=\"su-post-title\">Significant Impact of COVID-19 on HIV Care in Hospitals Affecting the First Pillar of the HIV Care Continuum<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">A study evaluating COVID-19 restrictions in the Netherlands between January and June 2020 found disruptions in clinical HIV care. During lockdown (March 16<\/span><span style=\"font-weight: 400\">th<\/span><span style=\"font-weight: 400\"> through May 31<\/span><span style=\"font-weight: 400\">st<\/span><span style=\"font-weight: 400\">), there was a significant reduction in the weekly number of HIV tests. The proportion of individuals newly diagnosed with HIV was also lower during lockdown, with a higher proportion presenting with advanced disease at entry to clinical care. The number of patients with HIV indicator conditions each month, such as hepatitis B\/C, cervical dysplasia\/cancer, and lymphoma, who entered care also decreased disproportionately between January and April, which the authors suggest may be due to closure of public health centers, patient delay due to fear of contracting SARs-CoV-2, and increased barriers to consulting with general practitioners.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Hensley et al.\u00a0(May 16, 2021). Significant Impact of COVID-19 on HIV Care in Hospitals Affecting the First Pillar of the HIV Care Continuum. Clinical Infectious Diseases. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1093\/cid\/ciab445\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1093\/cid\/ciab445<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<h2>Other Resources and Commentaries<\/h2>\n<ul>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.1093\/jamia\/ocab105\"><span style=\"font-weight: 400\">Accessibility Evaluation of COVID-19 Vaccine Registration Websites across the United States<\/span><\/a><span style=\"font-weight: 400\"> \u2013 Journal of the American Medical Informatics Association (May)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.1126\/science.abj3858\"><span style=\"font-weight: 400\">Israel\u2019s COVID-19 Endgame<\/span><\/a><span style=\"font-weight: 400\"> \u2013 Science (May)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.1101\/2021.05.06.21256757\"><span style=\"font-weight: 400\">COVID-19 Outbreak Rates and Infection Attack Rates Associated with the Workplace a Descriptive Epidemiological Study<\/span><\/a><span style=\"font-weight: 400\"> \u2013 MedRxiv (May 14)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.1016\/j.cmi.2021.05.006\"><span style=\"font-weight: 400\">Spreading of a New SARS-CoV-2 N501Y Spike Variant in a New Lineage<\/span><\/a><span style=\"font-weight: 400\"> \u2013 Clinical Microbiology and Infection\u202f(May)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.1136\/bmj.n1238\"><span style=\"font-weight: 400\">Covid-19: India Sees Record Deaths as \u201cBlack Fungus\u201d Spreads Fear<\/span><\/a><span style=\"font-weight: 400\"> \u2013 BMJ (May 13)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.1016\/S0140-6736(21)01097-7\"><span style=\"font-weight: 400\">Serbia Begins Paying Citizens to Receive a COVID-19 Vaccine<\/span><\/a><span style=\"font-weight: 400\"> \u2013 Lancet (May)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.1136\/bmj.n1197\"><span style=\"font-weight: 400\">Vaccinating Children against SARS-CoV-2<\/span><\/a><span style=\"font-weight: 400\"> \u2013 BMJ (May)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.1038\/d41586-021-01299-y\"><span style=\"font-weight: 400\">Delaying a COVID Vaccine\u2019s Second Dose Boosts Immune Response<\/span><\/a><span style=\"font-weight: 400\"> \u2013 Nature (May 13)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.1016\/S0140-6736(21)00894-1\"><span style=\"font-weight: 400\">Data Discrepancies and Substandard Reporting of Interim Data of Sputnik V Phase 3 Trial \u2013 Authors\u2019 Reply<\/span><\/a><span style=\"font-weight: 400\"> \u2013 The Lancet (May)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.1093\/cid\/ciab436\"><span style=\"font-weight: 400\">Evaluating the Presence of Replication-Competent SARS-CoV-2 from Nursing Home Residents with Persistently Positive RT-PCR Results<\/span><\/a><span style=\"font-weight: 400\"> \u2013 Clinical Infectious Diseases (May 14)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.1093\/infdis\/jiab260\"><span style=\"font-weight: 400\">Comparable Environmental Stability and Disinfection Profiles of the Currently Circulating SARS-CoV-2 Variants of Concern B.1.1.7 and B.1.351<\/span><\/a><span style=\"font-weight: 400\"> \u2013 The Journal of Infectious Diseases (May 16)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.1101\/2021.05.11.443443\"><span style=\"font-weight: 400\">SARS-CoV-2 Variant of Concern Substitutions Alter Spike Glycoprotein Receptor Binding Domain Structure and Stability<\/span><\/a><span style=\"font-weight: 400\"> \u2013 BioRxiv (May 14)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.1016\/j.jnma.2021.04.003\"><span style=\"font-weight: 400\">Amplifying Inequity: The Compounding Impact of COVID-19 and Violence<\/span><\/a><span style=\"font-weight: 400\"> \u2013 Journal of the National Medical Association (Apr)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.1001\/jamahealthforum.2021.0393\"><span style=\"font-weight: 400\">Trends in Filled Naloxone Prescriptions Before and During the COVID-19 Pandemic in the United States<\/span><\/a><span style=\"font-weight: 400\"> \u2013 JAMA Health Forum (May 14)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.1038\/d41591-021-00031-7\"><span style=\"font-weight: 400\">Tocilizumab for the Treatment of Severe COVID-19<\/span><\/a><span style=\"font-weight: 400\"> \u2013 Nature Medicine (May 13)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.1097\/QAD.0000000000002945\"><span style=\"font-weight: 400\">Safety and Antibody Response to the First Dose of SARS-CoV-2 Messenger RNA Vaccine in Persons with HIV<\/span><\/a><span style=\"font-weight: 400\"> \u2013 AIDS (May 14)<\/span><\/li>\n<li style=\"font-weight: 400\"><a href=\"https:\/\/doi.org\/10.1038\/s41541-021-00336-1\"><span style=\"font-weight: 400\">Comparative Systematic Review and Meta-Analysis of Reactogenicity, Immunogenicity and Efficacy of Vaccines against SARS-CoV-2<\/span><\/a><span style=\"font-weight: 400\"> \u2013 NPJ Vaccines (May 13)<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Report prepared by the UW Alliance for Pandemic Preparedness and Global Health Security and the START Center in collaboration with and on behalf of WA DOH COVID-19 Incident Management Team<\/span><\/i><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Interim results from a large study of US healthcare personnel indicated that one dose of either the Pfizer-BioNTech or Moderna vaccines was 82% effective against symptomatic COVID-19 and 2 doses were 94% effective.<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/05\/17\/significant-impact-of-covid-19-on-hiv-care-in-hospitals-affecting-the-first-pillar-of-the-hiv-care-continuum\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":6906,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[5],"tags":[],"topic":[],"class_list":["post-9824","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-covid-19-literature-situation-report"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9824","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=9824"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9824\/revisions"}],"predecessor-version":[{"id":9858,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9824\/revisions\/9858"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media\/6906"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=9824"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=9824"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=9824"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=9824"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}